Hemolysis Evaluation for Medical Devices: Standards, Test Methods, and Regulatory Compliance

Hemolysis evaluation is a critical biocompatibility test that measures the degree of red blood cell damage caused by medical devices and biomaterials that contact blood during clinical use. Conducted in accordance with ISO 10993-4, ASTM F756, and GB/T 16886.4, this assessment quantifies the hemolysis ratio of devices such as catheters, hemodialyzers, oxygenators, and vascular implants to support regulatory submissions worldwide. This article provides a comprehensive technical overview of hemolysis testing, including sample requirements, test methodologies, acceptance criteria, and practical applications in device development.

Technical Overview

Hemolysis evaluation is an in vitro biocompatibility test designed to determine whether a medical device or biomaterial damages red blood cells (erythrocytes) when it comes into direct or indirect contact with blood. When the erythrocyte membrane is disrupted by mechanical shear, surface chemistry, or leachable substances, hemoglobin is released into the surrounding plasma. Excessive hemolysis can lead to serious clinical consequences, including anemia, hemoglobinuria, renal tubular injury, and thromboinflammatory complications. Hemolysis testing is therefore a mandatory component of the biological safety evaluation for blood-contacting devices.

The test is primarily governed by ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood), with material-level methodology detailed in ASTM F756 (Standard Practice for Assessment of Hemolytic Properties of Materials) and the corresponding Chinese national standard GB/T 16886.4. In a typical assay, diluted anticoagulated rabbit or human blood is incubated with a test article or its extract, after which free hemoglobin released into the supernatant is quantified spectrophotometrically. The hemolysis ratio is calculated by normalizing the test result between positive and negative controls, providing a quantitative index of blood compatibility.

Regulatory authorities in major jurisdictions, including the FDA, EU notified bodies under the EU MDR, and NMPA reviewers, routinely require hemolysis data as part of biological evaluation files. Testing is typically performed by accredited third-party laboratories or in-house facilities operating under ISO/IEC 17025 quality systems to ensure data integrity and regulatory acceptance.

Testing Samples

Blood-Contacting Final Devices

Finished products intended for direct or indirect blood contact represent the most common sample category. Representative examples include:

• Intravascular catheters, cannulas, guidewires, and introducer sheaths
• Extracorporeal circulation circuits, membrane oxygenators, and ECMO components
• Hemodialyzers, hemoperfusion cartridges, and blood tubing sets
• Blood collection bags, transfusion sets, infusion sets, and in-line filters
• Vascular stents, grafts, heart valves, and septal occluders
• Ventricular assist devices, blood pumps, and cell salvage systems

Raw Materials and Polymer Coupons

During early-stage design and material screening, test coupons of candidate polymers, metals, ceramics, coatings, or elastomers are evaluated before tooling investment. Coupons should represent the final surface finish, curing condition, and sterilization state of the material as intended for clinical use.

Material Extracts

For the indirect contact method, extracts are prepared according to ISO 10993-12 at standard ratios such as 3 cm²/mL for surface-area-based samples or 0.2 g/mL for mass-based samples, using extraction vehicles such as saline or diluted blood-compatible media under defined temperature and duration conditions (for example, 37°C for 24 hours or accelerated conditions of 50°C for 72 hours).

Testing Items

The core analytical endpoints of a hemolysis evaluation typically include:

• Hemolysis ratio (hemolysis index): the percentage of hemoglobin released by the test article relative to the span between positive and negative controls
• Plasma free hemoglobin concentration: quantitative measurement of hemoglobin released into the supernatant after incubation and centrifugation
• Direct contact hemolysis: assessment of erythrocyte damage caused by physical interaction with the device surface
• Indirect contact (extract) hemolysis: assessment of hemolysis induced by leachable chemical substances extracted from the device
• Control verification: confirmation of negative control (for example, high-density polyethylene) and positive control (for example, sterile water for injection or a detergent solution) performance within expected ranges

Depending on the device classification under ISO 10993-4, hemolysis testing may be combined with complementary hemocompatibility endpoints such as thrombogenicity, complement activation (C3a, C5a), coagulation assays (PTT, PT), and platelet interaction studies.

Testing Methods

Direct Contact Method

In the direct contact assay, the intact test article is incubated with diluted, anticoagulated fresh rabbit or human blood (commonly a 2% erythrocyte suspension in physiological saline or PBS) at 37°C for a defined period, typically 2 to 4 hours with gentle agitation where applicable. Following incubation, samples are centrifuged to sediment intact erythrocytes, and the absorbance of free hemoglobin in the supernatant is measured spectrophotometrically, often at 540 nm using the cyanmethemoglobin (Drabkin's reagent) method. This approach evaluates the combined effects of surface texture, geometry, and mechanical shear on red blood cells.

Indirect Contact (Extraction) Method

In the extraction method, a material extract prepared per ISO 10993-12 is mixed with the diluted blood suspension and incubated at 37°C. Hemoglobin release is quantified identically to the direct method. This pathway isolates the chemical contribution of leachables such as residual monomers, plasticizers, antioxidants, sterilant residues, and processing additives, making it particularly suitable for devices with complex geometries or long-term circulating blood contact.

Calculation and Acceptance Criteria

The hemolysis ratio is calculated as: HR (%) = (OD_test − OD_{negative control}) / (OD_{positive control} − OD_{negative control}) × 100. Under GB/T 16886.4 and ASTM F756 conventions, a hemolysis ratio of 5% or less is generally interpreted as non-hemolytic and acceptable for most blood-contacting applications. Results between 5% and 10% typically warrant investigation, root-cause analysis, and possible design modification, while values above 10% are generally considered hemolytic and unacceptable. Interpretation should always account for the intended use, contact duration, and flow conditions of the device.

Applications

Hemolysis evaluation data serve multiple functions across the medical device product lifecycle:

• Regulatory submissions: supporting biological evaluation sections of 510(k) and PMA applications to the FDA, technical documentation under the EU MDR, and registration dossiers with the NMPA and other national authorities
• Material selection and design verification: comparing candidate polymers, coatings, metals, and surface treatments during research and development
• Change control: re-evaluating hemocompatibility after modifications to materials, suppliers, manufacturing processes, or sterilization methods
• Batch release and quality monitoring: periodic verification of production consistency for high-risk circulating-blood devices
• Scientific publication and standards development: generating reference data supporting blood-compatibility research

FAQ

Q: When is hemolysis testing required for a medical device?

A: Testing is required for devices with direct circulating blood contact (such as catheters, oxygenators, and stents) and for devices with indirect blood contact (such as infusion sets and cannulae that convey fluids into the vasculature). ISO 10993-4 contact categorization and a documented biological evaluation plan determine the exact scope.

Q: What blood source is used in the test?

A: Fresh anticoagulated rabbit blood is most commonly used, typically collected in heparin or citrate. Fresh human donor blood may also be used, particularly for device-specific evaluations, provided donor screening and ethical requirements are satisfied.

Q: What is the pass criterion for the hemolysis test?

A: A hemolysis ratio of 5% or less is generally accepted as non-hemolytic according to GB/T 16886.4 and ASTM F756 conventions. The acceptance threshold should nevertheless be justified against the device's intended clinical use and contact duration.

Q: What is the difference between the direct and indirect methods?

A: The direct method incubates the intact device with diluted blood and captures both mechanical and surface-mediated damage, whereas the indirect method tests a material extract and focuses on chemical leachables. Many submissions include both assays to provide comprehensive coverage of hemolytic mechanisms.

Q: How should samples be prepared before testing?

A: Samples should represent the final product in its sterilized, ready-to-use condition, with sterile handling throughout. Extraction conditions and surface-area-to-volume ratios follow ISO 10993-12 unless a scientific rationale supports an alternative protocol.

Q: Can hemolysis testing be performed with other hemocompatibility assays?

A: Yes. Hemolysis is frequently integrated into a broader ISO 10993-4 test panel that may include thrombosis, coagulation, platelet function, hematology, and complement activation endpoints, providing a complete hemocompatibility profile for blood-contacting devices.